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ABSTRACT
Polymorphisms in genes that encode antigen-presenting molecules, antigen receptors, and immune mediators
are crucial determinants of the risk of complications after allogeneic hematopoietic cell transplantation
(allo-HCT). Matching for HLA alleles remains the cornerstone of donor selection, and recent studies are
refining our understanding and use of HLA typing in allo-HCT. High-resolution allelic HLA matching
generally improves transplant outcome but may limit the donor pool and delay transplantation. Allelic
mismatches may be permissible in certain circumstances without compromising outcome. There is growing
interest in the role of natural killer (NK) cell–mediated immunity in allo-HCT. NK cells express an array of
activating and inhibitory killer cell immunoglobulin-like receptors (KIR), and NK cell activation is negatively
regulated by KIR interaction with HLA class I molecules. In haploidentical transplants, NK cell alloreactivity
in the graft-versus-host direction can be predicted by the HLA class I and KIR genotypes of donor and
recipient and has been associated with potent graft-versus-leukemic effects and low rates of graft-versus-host
disease. KIR genotype and expression may influence transplantation outcomes in both HLA-matched and -mis-
matched transplants. Graft-versus-host disease and major infection remain problematic despite HLA matching,
and there is mounting evidence that polymorphisms in non-HLA immune mediators and host defense genes
influence the risk of these complications. The importance of non-HLA genomics in nonmyeloablative trans-
plants is poorly understood and is under investigation. These findings suggest that tissue typing for allo-HCT
is entering an exciting era in which both HLA and non-HLA genomic data may be used in a more sophisticated
fashion to select donors, stratify risk, identify novel therapeutic targets, and ultimately improve outcome for
allo-HCT recipients.
© 2006 American Society for Blood and Marrow Transplantation
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tMMUNOGENETICS OF UNRELATED HEMATOPOIETIC
ELL TRANSPLANTATION
Understanding the genetic basis of graft-versus-
ost (GVH) and host-versus-graft allorecognition in
nrelated donor allogeneic hematopoietic cell trans-
lantation (allo-HCT) requires a full understanding of
LA genes and their interactions. The major histo-
ompatibility complex is the most comprehensively
tudied multimegabase region of the human genome.
uch of our knowledge of the immunogenetic basis
f alloreactivity comes from long-standing clinical ex- o
B&MTerience in the use of myeloablative conditioning reg-
mens and donor bone marrow as the grafting source.
nder these circumstances, donor T-cell recognition
f host HLA can give rise to graft-versus-host disease
GVHD), and host recognition of donor HLA may
ncrease the risk of graft failure. Methodologic ad-
ances in tissue typing have revolutionized the HLA
eld and applications to transplantation. These data
emonstrate that (1) high-resolution (allelic) DNA
yping methods can uncover functionally relevant
ransplant determinants, and, therefore, these meth-
ds are required for donor evaluation; (2) the risks of
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2raft rejection, GVHD, and mortality are increased
ith increasing numbers of HLA mismatches, and,
herefore, selection of the donor with the fewest mis-
atches may reduce complications; and (3) the risks of
raft rejection, GVHD, and mortality may be greater
ith mismatches detectable by low-level (antigen) res-
lution techniques than with mismatches detectable
nly by high-resolution methods, and, therefore, al-
ele-mismatched donors should be prioritized over
ntigen-mismatched donors [1]. A minority of patients
an ﬁnd fully matched donors, but all patients have a
ismatched donor. Current research priorities in-
lude the need for a more complete understanding of
he properties of HLA mismatches that do not in-
rease posttransplantation complications.
igh-Resolution Donor Matching in Support
f Unrelated HCT
The largest comprehensive analysis of donor-re-
ipient low-resolution (antigen) and high-resolution
allele) HLA matching, performed by the National
arrow Donor Program, uncovered a statistically sig-
iﬁcantly increased risk of mortality associated with
onor mismatching for HLA-A, -B, -C, and -DRB1
2]. Allele mismatches at each of HLA-A, -B, -C, and
DRB1 were less detrimental when compared with
atches at the appropriate locus than were antigen
ismatches for mortality. Finally, when compared
ith HLA-A and -B antigen–matched and -DRB1–
atched patients, those with an allele mismatch at
LA-A or -B or any mismatch at HLA-C had poorer
urvival and a higher incidence of acute GVHD.
The National Marrow Donor Program analysis
emonstrates that an optimal transplantation outcome
an be achieved through comprehensive and precise do-
or matching for HLA genes. Many patients in need of
n unrelated allo-HCT, however, do not have well-
atched donors; identiﬁcation of permissive locus- and
llele-speciﬁc mismatches will enable more patients to
eneﬁt from unrelated HCT with the judicious use of
ismatched donors. In addition, the disease stage at
he time of transplantation is an important factor in
he overall success of transplantation. For patients
ith advanced or active malignancy who may not have
ime for a lengthy unrelated donor search, the risks
nd beneﬁts of earlier transplantation from mis-
atched donors or deferral of transplantation until a
etter-matched donor can be identiﬁed are important
linical questions that remain to be addressed. Four
utcomes can arise in this situation: (1) a better-
atched donor is identiﬁed, and the disease remains
table; (2) a better-matched donor is identiﬁed, but the
isease advances; (3) a better-matched donor is not
dentiﬁed, but the disease remains stable; and (4) a
etter-matched donor is not identiﬁed, and the disease
rogresses. A single-center study found that the over-
ll survival of patients who received a transplant in l
0arly chronic phase (CP) of chronic myeloid leukemia
CML) from a mismatched donor was similar to the
urvival of patients who received a transplant in late
P from an HLA-identical donor; this suggested that
he potential beneﬁt of HLA matching was offset by
he negative effect of advanced disease [3]. Survival
ith an HLA-matched donor in late CP was similar to
hat with an HLA-mismatched donor in late CP. This
etrospective analysis of CML suggests that the in-
reased mortality associated with a longer time inter-
al from diagnosis to transplantation must be weighed
arefully against the increased mortality with earlier
ransplantation with a mismatched donor and also
gainst the chance of disease progression to advanced-
hase CML during a prolonged donor search.
ermissible Mismatches
Nucleotide substitutions that deﬁne unique HLA
lass I and II alleles are concentrated at residues that
esult in a change in the protein sequence and that
ontact either bound peptide or the T-cell receptor.
ne approach to better understand the clinical ramiﬁ-
ations of HLA diversity on function has been to exam-
ne a wide array of HLA allele and antigen mismatches
n racially diverse transplant populations (http://www.
hwg.org). An analysis by the International Histocom-
atibility Working Group in HCT of 2399 unrelated
ransplantations from North America, Europe, Asia,
nd Australia has enabled investigators to test the
ypothesis that the permissibility of HLA mismatches
s in part governed by the locus and the combination
f mismatched alleles or antigens.
Data contributed to the International Histocom-
atibility Working Group by the Japan Marrow Do-
or Program have provided a large group of transplan-
ations for comparison with the data on white patients
nd donors. In both the Japanese and the white data sets,
n increased hazard of death was associated with the
umber of mismatched alleles compared with 10/10 al-
ele matches. Locus-speciﬁc effects on mortality were
xamined for transplantation pairs with a single HLA
ismatch. Among white recipients, the presence of a
ingle HLA-C mismatch conferred an increased haz-
rd of mortality compared with a match, whereas an
LA-A mismatch was not associated with a statisti-
ally signiﬁcant increase in risk. In contrast, Japanese
ecipients had an increased risk of mortality associated
ith an HLA-A mismatch and not with HLA-C mis-
atching. Examination of the speciﬁc HLA-A and
LA-C mismatch combinations represented in the
apanese and white recipients and donors revealed
ajor differences between the allele combinations
ismatched for a given antigen. Similar ﬁndings at
ach HLA locus were uncovered, and this indicates
hat the study of permissible mismatches will require
arge numbers of ethnically and racially diverse trans-
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Blantation populations who have been characterized at
igh resolution and for whom complete clinical data
re available.
In conclusion, donor HLA disparity remains a
ajor cause of increased morbidity and mortality after
nrelated transplantation. The selection of prospec-
ive unrelated donors has historically been based on
LA matching for class I and II genes. Unmet needs
nclude information on qualitative and quantitative
easures of risk associated with HLA mismatching;
his information is required to best address the needs
f patients for whom a matched donor is not available.
he importance of structure as a way to understand
unction requires a systematic approach—one that in-
olves the examination of diverse populations to appre-
iate the full extent and nature of genetic variation and
he application of this information to the analysis of
linical populations, with careful attention to the
ransplantation procedures and the nongenetic factors
hat also inﬂuence outcome.
ATURAL KILLER CELLS AND ALLO-HCT OUTCOME
Studies showing marked variation in survival and
VHD in haploidentical transplants according to pre-
icted natural killer (NK) cell alloreactivity have stim-
lated intense interest in the role of NK cells in
llo-HCT. NK cells are lymphocytes of the innate
mmune system that act early in immune responses to
yse infected or malignant cells [4,5]. NK cells recon-
titute early after allo-HCT and have been implicated
n suppression of GVHD, promotion of engraftment,
nd graft-versus-leukemia (GVL) effects. Unlike T
ymphocytes, NK cells do not rearrange antigen-re-
eptor genes to generate highly antigen-speciﬁc re-
eptors, but they express several groups of activating
nd inhibitory killer cell immunoglobulin-like recep-
ors (KIR; Table 1). The KIR genes lie on chromo-
ome 19. Diversity in the KIR genotype is determined
y the number and type of KIR genes present in each
IR haplotype, allelic polymorphism in each KIR
ene, and the combination of maternal and paternal
aplotypes [6]. Many KIR recognize HLA class I mol-
cules, but unlike T-cell antigen receptors, these in-
eractions are inhibitory rather than activating. This
nhibitory interaction is essential to prevent NK kill-
ng of autologous cells. The epitopes recognized by
hese inhibitory KIR are determined by speciﬁc amino
cid residues of HLA class I molecules, particularly
esidue 80 of the 1 helix of HLA-C (Table 2). NK
ells also express a lectin-like receptor, CD94-NKG2A,
hat recognizes HLA-E complexed with peptides de-
ived from HLA class I molecules.
The interaction between KIR and HLA class I
IR epitopes is an important determinant of NK
lloreactivity and can be predicted by the HLA class I w
B&MTypes of donor and recipient. Two dominant patterns
f alloreactivity are determined by an asparagine/ly-
ine dimorphism at HLA-C position 80: KIR2DL1
ecognizes HLA-Clys80, and KIR2DL2/3 recognize
LA-CAsn80. In HLA-C–mismatched transplantations,
K alloreactivity may occur in the GVH (and GVL)
irection if the donor possesses HLA-C motifs that
re missing in the recipient; these are then sensed by
onor NK cells as “missing self.” Similarly, host-
ersus-graft NK alloreactivity may occur if the recip-
ent possesses HLA-C motifs that are absent in the
onor.
K Alloreactivity in Haploidentical
ransplantations
The potential importance of KIR ligand matching
as identiﬁed by data from haploidentical transplan-
ations, in which only 1 of 2 HLA haplotypes is shared
etween donor and recipient. The use of haploiden-
ical donors has the potential to expand the donor
ool, but such transplantations require more intensive
mmunosuppression (eg, T-cell depletion) to mini-
ize the risk of graft rejection and severe GVHD. In
he Perugia study of T cell–depleted unrelated hap-
oidentical transplantations, NK alloreactivity was
redicted by donor and recipient HLA-C typing and
able 1. NK Cell Receptors and Ligands
Variable Ligand
nhibitory NK receptors
KIR2DL1 HLA-C group 2 (amino acids
Asn77 and Lys80), eg, Cw2,
Cw4, Cw5, Cw6
KIR2DL2/3 HLA-C group 1 (Ser77 and Asn
80), eg, Cw1, Cw3, Cw7, Cw8
KIR3DL1 HLA-B alleles containing the
Bw4 motif, eg, B5, B13, B17,
B27, B44, B52, some B15
KIR3DL2 HLA-A3 and A11
KIR3DL3 Unknown
CD94/NKG2A HLA-E complexed with HLA-A,
-B, -C, or G peptide
ctivating NK receptors
KIR2DS1 HLA-C
KIR2DS2 Unknown
KIR2DS3 Unknown
KIR2DS4 HLA-C
KIR2DS5 Unknown
KIR3DS1 Unknown
KIR2DL4 HLA-G
CD94/NKG2C HLA-E complexed with HLA-A,
-B, -C, or G peptide
NKG2D MICA, MICB, ULBP
nknown
NKG2E, NKG2F,
NKRP1A
Unknown
ICA indicates MHC class I polypeptide-related sequence A;
MICB, MHC class I polypeptide-related sequence B; ULBP,
UL16 binding protein.as also assessed by in vitro assays. Very low rates of
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22raft rejection, disease relapse, and mortality were
bserved in transplants with KIR ligand incompatibil-
ty and NK alloreactivity in the GVH direction [7]. It
s important to note that this was accompanied by low
ates of GVHD that were attributed to NK-mediated
epletion of recipient antigen-presenting cells. This
ffect was seen only in patients with acute myeloid
eukemia (AML) and not acute lymphoblastic leuke-
ia (ALL), a ﬁnding attributed to low lymphoblast
xpression of the adhesion molecules necessary for
K/target cell interaction. These results were updated
n a larger group of AML patients (n  80), again
howing strikingly low relapse (17% versus 79%) and
uperior event-free survival (52% versus 7%) in trans-
lantations from NK-alloreactive donors compared
ith transplantations with no NK alloreactivity [8].
ubsequent studies of haploidentical and unrelated
ransplantations (in which HLA-C mismatching was
elatively common) have yielded conﬂicting data re-
arding the clinical importance of NK alloreactivity
9-14]. This may in part be due to differences in
ransplantation protocols, particularly the intensity of
-cell depletion [15], stem cell dose, and posttrans-
lantation immunosuppression, all of which may in-
uence NK cell dose, engraftment, and alloreactivity.
urthermore, consideration of other determinants of
K alloreactivity, such as KIR genotype, may be im-
ortant, as discussed below.
K Alloreactivity in HLA-Matched
ransplantations
The “missing self” model of NK alloreactivity
redicted by HLA disparity described previously
as been informative in HLA-C–mismatched trans-
lantations but is not applicable to HLA-matched
ransplantations. Furthermore, HLA-C genotype
lone is insufﬁcient to predict NK alloreactivity in
ome donor-recipient combinations. The KIR
enes are located at chromosome 19q13.4 and seg-
egate independently from HLA on chromosome 6.
rediction of NK alloreactivity may be improved by
onsidering the KIR genotype in addition to HLA
lass I typing. A recent study that examined donor
IR and recipient KIR ligand (ie, HLA class I)
enotype in 178 HLA-matched sibling T cell–de-
leted transplantations found that 62.9% of trans-
lant pairs lacked a recipient KIR ligand for donor
IR. Missing KIR ligand was an independent risk
actor for relapse in patients who underwent trans-
lantation for AML and myelodysplasia [16]. This
missing ligand” model suggests that NK alloreac-
ivity can occur in HLA-matched transplantations if
he recipient lacks an HLA ligand for donor KIR
nd suggests that KIR genotyping should be per-
ormed in addition to HLA genotyping. The poten-
ial importance of the interaction between donorable 2. Summary of Non-HLA Genetic Associations with
llo-HCT Outcome
Gene and Polymorphism Association
NF d VNTR, 488 SNP Acute and chronic GVHD,
mortality
NF a and d VNTRs, 1031
SNP
Survival*
NF 1031T/863C/857C
haplotype
Acute GVHD*
NF 308 SNP Neutrophil engraftment*
NFRSF1B 196 SNP Relapse, acute GVHD*
FNG intron 1 (CA)n VNTR Acute GVHD,† chronic
GVHD
L1A 889 SNP Chronic GVHD,* survival, and
TRM*
L1B 511, 3954 SNPs Hepatic acute GVHD,
survival, and TRM*
L1RN*2 VNTR Acute and chronic GVHD
L2 330 SNP Acute GVHD*
L6 174 SNP Acute and chronic GVHD
L10 1064 VNTR Acute and chronic GVHD
L10 promoter SNPs Acute and chronic GVHD,
survival‡
L10RB 238*G SNP Acute GVHD
L18 promoter SNPs Survival, TRM*
GFB1 coding SNPs,
TGFB1RII 1167 SNP
Acute GVHD
ARD15 SNPs Acute GVHD, gut GVHD,
mortality‡
SR1 intron 1 PX haplotype Acute GVHD, survival
DR ApaI SNP Acute GVHD, survival
CE D/D genotype Noninfectious pulmonary
dysfunction
CGR2A aa131 SNP Time to first infection
CGR3B genotype Time to neutrophil recovery,
mortality
STM1 null genotype Hepatic VOD
BL2 coding mutations,
HYA haplotype
Major infection
PO 463 SNP Bacterial infection
THFR 677 SNP Mucositis
ERPINE 4G/4G Catheter thrombosis†
NFRSF6 (Fas) Acute GVHD, major infection
ll studies listed examined HLA-matched myeloablative transplan-
tations unless otherwise indicated.
CE indicates angiotensin-conveting enzyme; CARD15, caspase
recruitment domain family, member 15; ESR1, estrogen receptor 1
(); FCGR2A, FCGR3B, low-afﬁnity receptor for Fc fragment of
immunoglobulin G, types IIa and IIIb; GSTM1, glutathione-S-
transferase M1; IFNG, interferon ; IL, interleukin; IL1RN, IL-1
receptor antagonist; MBL2, mannose-binding lectin; MPO, my-
eloperoxidase; MTHFR, methylene tetrahydrofolate reductase;
SERPINE, serpin peptidase inhibitor, clade E, also known as
plasminogen-activator inhibitor; TGFB, transforming growth
factor ; TNF, tumor necrosis factor; TNFRSF1B, TNF recep-
tor 2; TNFRSF6, Fas (Apo 1); TRM, treatment-related mortal-
ity; VNTR, variable number of tandem repeats (microsatellite);
SNP, single nucleotide polymorphism; VOD, veno-occlusive
disease.
Unrelated donor transplantations.
Myeloablative and nonmyeloablative transplantations.IR and recipient KIR ligand in HLA-matched
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Bransplantations is supported by recent data show-
ng that patients who lack expression of HLA-C
roup 1 alleles have a higher risk of relapse and
educed survival [17,18]. Furthermore, because not
ll individuals with a given KIR genotype express
he corresponding receptor at the cell surface [19],
IR phenotyping by ﬂow cytometry may be re-
uired to provide the most accurate prediction of
K alloreactivity. The roles of HLA-C and KIR
enotype in predicting NK alloreactivity are shown
n Figure 1.
The expression of activating KIR also varies be-
ween individuals, and it is possible that activating
IR genotype inﬂuences allo-HCT outcome. Current
ata are inconclusive. Several studies have examined do-
or activating KIR genotype in HLA-identical sibling
ransplantations; some have detected associations be-
ween activating KIR, such as KIR2DS1 and KIR2DS2,
nd the risk of relapse [20,21], but others have not
16,18]. It is interesting to note that recent studies
ave found that recipient KIR genotype may also
igure 1. Use of KIR and HLA-C type to predict GVL effec
onor-recipient combinations of HLA-C (KIR) epitopes. For each c
peciﬁc (KIR2DL1) and HLA-Casn80–speciﬁc (KIR2DL3) KIRs and
ach donor are the subpopulations of NK cells that express KIR2DL
eceptors for autologous major histocompatibility complex (MHC
LA-Clys80 but has only HLA-Casn80–speciﬁc (KIR2DL3) KIRs,
eceptors for autologous MHC class I molecules. NK cell subpopul
o); those that are predicted to be inhibited by the recipient’s HLA
hich knowledge of the HLA-C type is insufﬁcient to predict the
lso required, are emphasized in bold. For simplicity, the additional
imilar considerations apply to it. The icons for KIRs and their cogn
n orange, and KIR2DL3 and HLA-Casn80 are shown in purple. R
acmillan Magazines Ltd. (http://www.nature.com/reviews).nﬂuence the risk of relapse and GVHD [18,22]. I
B&MTK Alloreactivity in Clinical Practice
How might NK alloreactivity be exploited to im-
rove transplantation outcomes? Existing data suggest
hat NK alloreactivity inﬂuences outcome in both HLA-
ismatched and HLA-matched transplantations and is
etermined by both HLA class I and KIR genotype.
onor selection based on NK alloreactivity may im-
rove the efﬁcacy and safety of haploidentical trans-
lantations and considerably expand the pool of avail-
ble donors for recipients who lack an HLA-matched
onor. In this setting, HLA typing may be used to
dentify recipients who are potentially susceptible to
K-mediated alloimmune responses. Recipients who
xpress all 3 major HLA class I KIR ligands are likely
o be resistant to NK-mediated lysis. Donor HLA
ype can then be used to identify potential donors that
xpress HLA class I not present in the recipient. KIR
yping, KIR allelic typing, and immunophenotyping
ay also be required to more accurately determine
onor KIR expression and activating KIR genotype.
alloreactivity in the GVH direction is depicted for 9 possible
ation, donors of 2 KIR types are considered: 1 having HLA-Clys80–
her having only HLA-Casn80–speciﬁc (KIR2DL3) KIRs. Shown for
2DL3, or both and that use these receptors as their only inhibitory
I molecules. For example, in the donor who is homozygous for
are no NK cells using HLA-C–speciﬁc KIRs as their inhibitory
hat are predicted to mediate GVL reactions are colored green (for
e are colored red (for stop). The donor-recipient combinations for
ility of a GVL effect, and for which knowledge of the KIR type is
asn80–speciﬁc KIR (KIR2DL2) is not included in this example, but
A-C ligands are color coded: KIR2DL1 and HLA-Clys80 are shown
ced with permission from Nature Reviews Immunology (5) © 2003ts. NK
ombin
the ot
1, KIR
) class
there
ations t
-C typ
probab
HLA-C
ate HL
eprodun the HLA-matched transplantations, it will be of
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2reat interest to examine the importance of KIR ge-
otype in conjunction with other clinical and genetic
ariables, such as cytokine genotype. At present there
re few data that examine KIR genomics in nonmy-
loablative transplantations. Because NK reconstitu-
ion (and, thus, GVL responses) may be signiﬁcantly
ifferent in nonmyeloablative transplantations com-
ared with myeloablative transplantations, this area
equires further study. It may also be possible to ex-
and alloreactive NK cells ex vivo for subsequent
herapeutic use [23]. This is of particular importance
or patients who possess a full complement of inhibi-
ory KIR ligands, who are less susceptible to donor
K-mediated GVL effects.
ON-HLA GENETIC DETERMINANTS OF
RANSPLANTATION OUTCOME
Interest in the relationship between non-HLA im-
unogenetic polymorphisms and the risk of compli-
ations after allo-HCT has been driven by several
bservations. First, severe GVHD remains a common
omplication in HLA-matched transplantations. Sec-
nd, the pathogenesis of GVHD is a complex, multi-
tep process that involves conditioning-induced organ
amage and the induction of high levels of inﬂamma-
ory cytokines that augment tissue damage and donor
ymphocyte activation. Polymorphisms in the genes that
ncode these inﬂammatory mediators inﬂuence the level
f expression or activity of the encoded mediators and
ay inﬂuence GVHD pathogenesis. Third, the genetic
actors that inﬂuence the risk of other complications,
uch as chronic GVHD and infection, are less well
nderstood, and it is possible that polymorphisms in
nﬂammatory mediators and host defense genes are
mportant.
on-HLA Immunogenetics and GVHD
A widely accepted paradigm of acute GVHD patho-
enesis is a 3-step model in which (1) pretransplantation
onditioning induces recipient tissue damage, (2) allo-
eactive donor T cells are activated and expand, and (3)
ellular and inﬂammatory effectors result in tissue dam-
ge [24]. Chemotherapy and radiotherapy damage or-
ans such as the gut and liver, resulting in upregula-
ion of inﬂammatory cytokines such as tumor necrosis
actor (TNF) and interleukin (IL)–1, as well as trans-
ocation of microbial products such as lipopolysaccha-
ide and CpG that further augment immune re-
ponses. These inﬂammatory cytokines increase the
xpression of HLA and costimulatory molecules on
ntigen-presenting cells and activate donor T cells,
hich secrete additional cytokines, such as IL-2 and
nterferon . Several other proinﬂammatory and anti-
nﬂammatory cytokines have also been implicated in
VHD pathogenesis, including IL-4, IL-5, IL-10, I
4L-12, IL-15, and IL-18. Secretion of chemokines
ay also be important in recruiting activated T cells
o sites of tissue injury. A variety of effectors and
athways damage recipient tissues, including the di-
ect action of cytokines, cytotoxic lymphocytes via Fas
nd perforin, NK cells, and nitric oxide.
Cytokine genes were among the ﬁrst non-HLA
andidate genes to be studied in allo-HCT outcome.
wealth of data support the importance of cytokines
n GVHD pathogenesis, including murine models of
VHD showing that blockade of or administration of
ytokines modulates the severity of GVHD and clin-
cal data showing that changes in blood cytokine levels
re associated with the risk and severity of GVHD.
he profound upregulation in cytokine synthesis in
he peritransplantation period has been termed a cyto-
ine storm. Most cytokine genes contain common in-
erited polymorphisms, many of which are located in
pstream or intronic regulatory regions or in down-
tream regions that may inﬂuence messenger RNA
tability. The polymorphisms are commonly short nu-
leotide sequences that display variable numbers of
epetitions (variable numbers of tandem repeats, or
icrosatellites) or single nucleotide polymorphisms.
any of the polymorphisms studied in allo-HCT are
ssociated with variation in cytokine synthesis in vitro
nd have been associated with a range of inﬂamma-
ory, autoimmune, and infectious diseases.
Most studies of non-HLA polymorphisms and
llo-HCT outcome have examined the risk and sever-
ty of acute GVHD in HLA-matched related donor
yeloablative transplantations. There are fewer data
egarding unrelated donor and nonmyeloablative
ransplantations and other outcomes such as chronic
VHD, infection, interstitial pneumonitis, and veno-
cclusive disease. Associations between TNF and IL10
ene polymorphisms and acute GVHD risk and se-
erity are among the earliest and most consistently
eported observations (see reviews [25,26]). TNF is an
mportant inﬂammatory cytokine that is upregulated
uring acute GVHD, and IL-10 antagonizes the re-
ease and many of the actions of TNF. The large
umber of studies implicating TNF and IL10 poly-
orphisms in GVHD risk, and other reports of asso-
iations with TNF and IL-10 receptor genes, suggest
hat these associations are biologically important. Sev-
ral other cytokine and immunoregulatory gene poly-
orphisms have been repeatedly associated with
VHD, such as a functional polymorphism in the IL6
ene promoter, an intronic microsatellite polymor-
hism in the interferon  gene, and polymorphisms in
he IL1 gene family. Polymorphisms in several genes
hat encode noncytokine immune mediators, such as
he vitamin D receptor and estrogen receptor, have
lso been associated with GVHD and survival. Poly-
orphisms in the TNF, TNFRSF1B (TNF receptor),L1, IL6, and IL10 genes have also been associated
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Bith chronic GVHD. These studies are summarized
n Table 2.
ssociations with Other Allo-HCT Outcomes
Fewer studies have examined associations with
on-GVHD outcomes, perhaps in view of the dif-
culty in rigorously detecting and evaluating these
nd points. However, several potentially important
ssociations have been reported. We and others
ave described associations between MBL2 gene
olymorphisms and major infection after transplan-
ation [27]. MBL2 encodes mannose-binding lectin
MBL), an innate host-defense molecule that di-
ectly recognizes a diverse array of pathogens and
riggers complement activation. Up to 40% of
ealthy individuals have low MBL levels, and there is
ntense interest in MBL-replacement therapy to amelio-
ate infection in a variety of clinical contexts. Polymor-
hisms in the myeloperoxidase gene MPO and the
mmunoglobulin receptor gene FCGRIIA have also
een associated with infection [28]. It is likely that
tudies examining additional host defense genes and
nfection will be informative.
Several pharmacogenomic studies have also been
eported. Methotrexate is a widely used immunosup-
ressive agent in allo-HCT and contributes to signiﬁ-
ant toxicity, such as mucositis. Methotrexate metabo-
ites inﬂuence the activity of methylene tetrahydrofolate
eductase, and polymorphisms in the MTHFR gene
ave been associated with mucositis, delayed platelet
ngraftment, and relapse. Polymorphisms in the
STM1 gene, which encodes a glutathione-S-trans-
erase involved in the metabolism of busulfan, have
een associated with the risk of veno-occlusive disease.
t is feasible that more detailed pharmacogenomic
tudies will permit individualized dosing to reduce the
isk of these complications.
imitations of Current Non-HLA Genomic Data
Non-HLA immunogenetic data may be used
linically to reﬁne donor selection, to identify re-
ipients at the highest risk of GVHD and inform
ounseling before transplantation, or to modify im-
unosuppressive strategies. These data might also be
sed to design or guide the use of novel therapies, such
s cytokine blockade or MBL-replacement therapy.
owever, there are several important limitations of
ost existing studies that must be addressed before
on-HLA genotyping enters clinical use.
Lack of reproducibility. Many reported associations
ave not been conﬁrmed in subsequent studies.
Sample issues. Many studies have examined small
ransplantation cohorts that are highly heteroge-
eous in terms of patient characteristics and trans-
lantation parameters.Genotyping issues. All reported studies have used a t
B&MTimited candidate gene approach. Many potentially
mportant genes and polymorphisms have not been
nvestigated. Consequently, it is very difﬁcult to
etermine which polymorphic marker represents
he strongest association with an outcome and is the
ost suitable for clinical use.
Donor versus recipient. Many studies have exam-
ned only recipient genotype. It is likely that both
onor and recipient genotypes are important, de-
ending on the clinical context and gene studied.
here both genotypes have been examined, the
elative importance of donor versus recipient geno-
ype has often differed between studies.
Statistical issues. Many studies have not applied
igorous statistical methods, such as conﬁrmation of
esults in independent cohorts, correction for mul-
iple comparisons, or multivariable analysis. Many
tudies are likely to contain false-positive and false-
egative associations. Few studies have examined
nteraction between multiple non-HLA genetic as-
ociations.
Nonmyeloablative transplantations. Reduced-inten-
ity conditioning regimens are associated with less early
oxicity; however, (delayed) acute and chronic GVHD
emain major problems. In view of the differences in
onditioning-induced organ damage and cytokine in-
uction between nonmyeloablative and myeloablative
ransplantations [29], it is likely that distinct non-HLA
ssociations will be seen in this setting.
ONCLUSIONS AND FUTURE PROSPECTS
We are entering an era when detailed HLA and
on-HLA genomic information may be used to im-
rove the outcome of allo-HCT. Large studies have
ocumented the importance of allelic HLA match-
ng in unrelated transplantations and are deﬁning
ermissible mismatches that will allow transplanta-
ions to be performed expeditiously without in-
reasing risk. Existing data suggest that non-HLA
olymorphisms and genetically determined NK al-
oreactivity also inﬂuence allo-HCT outcome, and
here is intense interest in using this information
linically. Before this is done, many of the limita-
ions of the existing studies described previously
ust be addressed. Many conﬂicting results are
ikely due to relatively small cohorts and differences
n transplantation practices. Carefully designed pro-
pective studies of large, homogeneous transplanta-
ion cohorts examining multiple genomic variants
re needed to deﬁnitively conﬁrm or refute associ-
tions; to examine interaction between multiple ge-
etic and clinical variables; and to construct predic-
ive models of risk that can inform transplantation
ractice. These studies must be performed in mul-
iple clinical settings: HLA-matched sibling, HLA-
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2atched unrelated, and haploidentical transplanta-
ions; transplantations using myeloablative and
onmyeloablative conditioning regimens; and cord
lood transplantation. It will be difﬁcult for all but
he largest centers to conduct studies in isolation
hat examine multiple genetic and clinical variables
ith sufﬁcient power, and collaborative studies will
e essential. It will be important for non-HLA
enomic studies to genotype each gene as compre-
ensively as possible, at least including all variants
hat have been previously examined. Newer mi-
roarray-based strategies offer a convenient way to
enotype many thousands of loci and polymor-
hisms either on a genome-wide basis or by provid-
ng high-density coverage of genes and polymor-
hisms within a particular functional group. For
K/KIR studies, genotyping of KIR ligand and
IR receptors in both donor and recipient will be
mportant. Ideally, genotyping strategies will be
oupled to studies that examine the functional ef-
ects of polymorphisms, for example, by measuring
lood levels or tissue expression of encoded medi-
tors or by in vitro assays of NK alloreactivity. As
he number of associated genetic variants increases,
t will remain important to conﬁrm associations in
linically similar independent cohorts.
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